ArticleCancers2013
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Cancer biology & therapy · 2015Pooled it
- Trial
- Nucleobindin 2 inhibits senescence in gastric carcinoma.Scientific reports · 2024Article
- Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.Frontiers in oncology · 2023Review
- SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway.Canadian journal of gastroenterology & hepatology · 2023Article
- Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration.Oncology reports · 2021Article
- Network Pharmacology and Molecular Docking Study of Zhishi-Baizhu Herb Pair in the Treatment of Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Silencing of LncRNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Inhibits the Proliferation and Promotes the Apoptosis of Gastric Cancer Cells Through Regulating microRNA-22-3p-Mediated ErbB3.OncoTargets and therapy · 2020Article
- High expression of MRE11 correlates with poor prognosis in gastric carcinoma.Diagnostic pathology · 2019Article
- Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.Journal of clinical medicine · 2019Article
- miR-384 targets metadherin gene to suppress growth, migration, and invasion of gastric cancer cells.The Journal of international medical research · 2019Article
- NADPH oxidase 4 is correlated with gastric cancer progression and predicts a poor prognosis.American journal of translational research · 2019Article
- Knockdown of long noncoding RNA GHET1 inhibits cell‑cycle progression and invasion of gastric cancer cells.Molecular medicine reports · 2018Article
- SSH1 expression is associated with gastric cancer progression and predicts a poor prognosis.BMC gastroenterology · 2018Article
- MFAP2 promotes epithelial-mesenchymal transition in gastric cancer cells by activating TGF-β/SMAD2/3 signaling pathway.OncoTargets and therapy · 2018Article
- An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.American journal of cancer research · 2018Article
- Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma.World journal of gastroenterology · 2017Article
- DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Targeted therapies in gastric cancer treatment: where we are and where we are going.Investigational new drugs · 2016Review
- Emerging molecular classifications and therapeutic implications for gastric cancer.Chinese journal of cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due to its insidious nature, presentation is usually late and often carries a poor prognosis. Despite having improved treatment modalities over the last decade, for most patients only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and its signaling pathways, offers the hope of clinically significant promising advances for selected groups of patients. Patients with Her-2 overexpression or amplification have experienced benefit from the integration of monoclonal antibodies such as trastuzumab to the standard chemotherapy. Additionally, drugs targeting angiogenesis (bevacizumab, sorafenib, sunitinib) are under investigation and other targeted agents such as mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors are in preclinical or early clinical development. Patient selection and the development of reliable biomarkers to accurately select patients most likely to benefit from these tailored therapies is now key. Future trials should focus on these advances to optimize the treatment for GC patients. This article will review recent progress and current status of targeted agents in GC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.